Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations
JCO Oncology Practice · 2025-06 · 21 (6) · 759-765
DOI: 10.1200/op.24.00387 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2025-06. Verfasst von Mohammed Munavvar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston, United Kingdom. Hauptthemen laut MEDLINE: Pleural Effusion, Malignant. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Malignant pleural effusion (MPE) is common in individuals with cancer and typically reflects advanced disease. Most cases are symptomatic, with dyspnea and pain having a severe effect on the patient's quality of life (QOL). The management of MPE aims to relieve symptoms, improve QOL, prevent repeated pleural interventions, and minimize hospital admissions. Common treatments for MPE that provide symptomatic relief include thoracentesis, chemical (talc) pleurodesis, or indwelling pleural catheters (IPCs). Talc pleurodesis and IPCs are the mainstay of treatment but represent very different treatment strategies: talc pleurodesis is an inpatient procedure, whereas IPCs are an ambulatory strategy. Given their similar efficacy, treatment decisions in MPE are often determined by other factors, such as the patient's clinical characteristics, individual treatment goals, and preferences for hospital-based or home-based care. We provide a summary of the evidence for different interventions for treating MPE and compare recommendations from the major American, European, British, and Spanish guidelines regarding when to consider each treatment. We highlight specific challenging treatment scenarios and key clinical considerations that may influence treatment decisions for different patients. There are barriers to accessing and receiving evidence-based care. Patients with symptomatic MPE would benefit from early referral from oncology teams to pleural services. We provide best practice recommendations for optimal referral and coordination of care to ensure that patients receive maximum benefits from their interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Respiratory Medicine, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston, United Kingdom.
- University of Central Lancashire, Preston, United Kingdom.
- Department of Respiratory Medicine, Zealand University Hospital, Næstved, Denmark.
- Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
- Interventional Pulmonology Unit, Pulmonology Department, Salamanca University Hospital, Salamanca, Spain.
- Department of Respiratory Medicine, The Princess Alexandra Hospital NHS Trust, Harlow, Essex, United Kingdom.
ORCID-Profile: Mohammed Munavvar, Andreas Carus, Samir Naik, Antonieta Salud, José M Porcel
Zitieren
APA
Munavvar, M., Bodtger, U., Carus, A., Cordovilla, R., Naik, S., Salud, A., & Porcel, J. M. (2025). Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations. JCO Oncology Practice, 21(6), 759-765. https://doi.org/10.1200/op.24.00387
Vancouver
Munavvar M, Bodtger U, Carus A, Cordovilla R, Naik S, Salud A, et al. Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations. JCO Oncology Practice. 2025;21(6):759-765. doi:10.1200/op.24.00387
BibTeX
@article{Munavvar2025,
author = {Munavvar, Mohammed and Bodtger, Uffe and Carus, Andreas and Cordovilla, Rosa and Naik, Samir and Salud, Antonieta and Porcel, José M},
title = {Current Trends in Treating Malignant Pleural Effusion: Evidence, Guidelines, and Best Practice Recommendations},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {6},
pages = {759--765},
doi = {10.1200/op.24.00387}
}
EUVIMED